These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

928 related articles for article (PubMed ID: 25350685)

  • 1. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
    Zeng H; Zhang H; Jang F; Zhao L; Zhang J
    Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
    J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
    Costantino G; Macchiarulo A; Camaioni E; Pellicciari R
    J Med Chem; 2001 Nov; 44(23):3786-94. PubMed ID: 11689065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
    Tripuraneni NS; Azam MA
    J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1.
    Fatima S; Bathini R; Sivan SK; Manga V
    J Recept Signal Transduct Res; 2012 Aug; 32(4):214-24. PubMed ID: 22713102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
    Choubey SK; Jeyaraman J
    J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction of pharmacophore model of PARP-1 inhibitor].
    Zhang WT; Yan H; Jiang FC
    Yao Xue Xue Bao; 2007 Mar; 42(3):279-85. PubMed ID: 17520827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the effect of PARP-1 flexibility in docking studies.
    Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A
    J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors.
    Nilov DK; Yashina KI; Gushchina IV; Zakharenko AL; Sukhanova MV; Lavrik OI; Švedas VK
    Biochemistry (Mosc); 2018 Feb; 83(2):152-158. PubMed ID: 29618301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
    Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
    J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
    Kaur M; Silakari O
    J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
    Gurung AB; Aguan K; Mitra S; Bhattacharjee A
    J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.
    Gohlke BO; Overkamp T; Richter A; Richter A; Daniel PT; Gillissen B; Preissner R
    BMC Bioinformatics; 2015 Sep; 16():308. PubMed ID: 26403354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
    Qiu Y; Zhou L; Hu Y; Bao Y
    J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics simulations.
    Dong L; Feng R; Bi J; Shen S; Lu H; Zhang J
    J Mol Model; 2018 Mar; 24(4):86. PubMed ID: 29511885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.